Compare Charles River Laboratories Intl. Inc (CRL) vs OneSpan Inc (OSPN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs OneSpan Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $302.12 (market cap $14.23B), while OneSpan Inc trades at $18.09 (market cap $662.97M). The key difference: Charles River Laboratories Intl. Inc is far larger — about 21.5× OneSpan Inc's market cap, and OneSpan Inc pays a 2.89% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and OneSpan Inc for 18 Days on average.
| CRL | OSPN | |
|---|---|---|
Market Cap | $14.23B | $662.97M |
Volume | 1,176,885 | 616,882 |
Sector | Health | Technology |
52-Week High | $310.77 | $18.42 |
52-Week Low | $149.93 | $10.15 |
Typical Hold Time | 33 Days | 18 Days |
Enterprise Value | $17.06B | $632.05M |
Dividend Yield | — | 2.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $300.53, up 0.08% on the day, with a bullish technical outlook and strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, though it faces profitability challenges with a negative net income margin and ROE. Recent investor day presentations highlighted a strategic plan targeting 5-7% revenue growth and $300 million in savings by 2030, driving positive sentiment.
The outlook is cautiously optimistic, supported by analyst buy ratings and a $305.50 consensus price target, but risks include ongoing margin pressure, volatile non-human primate costs, and a high valuation multiple. Earnings growth and successful execution of the new strategic plan are critical for sustained upside.
OneSpan (OSPN) trades at $17.70, down 3.7% in the last session, but maintains strong fundamentals with consistent earnings beats and robust profitability. The stock shows a bullish technical signal with support at $17 and resistance at $18. Recent Q2 2026 results exceeded expectations with EPS of $0.30 versus $0.231 expected, while the company introduced new authentication technology to drive future growth.
The outlook remains positive given strong analyst support (66.7% buy ratings) and solid financial metrics, though investors should monitor declining cash flow trends and competitive pressures in the cybersecurity sector. The stock presents value opportunity with P/E of 10.16 and ROE of 26.51%, but faces execution risks in maintaining subscription revenue growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About OneSpan Inc
OneSpan Inc. is a global leader in providing digital agreement security solutions. The company's platform helps organizations, primarily in the financial services sector, to secure their digital agreements and transactions, including e-signatures, multi-factor authentication, and transaction monitoring. OneSpan's technology is focused on protecting customers from fraud and meeting regulatory compliance requirements in a digital-first environment.
Read more on OSPN →
